Trials / Completed
CompletedNCT02944383
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- NeuroBo Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcabene | Gemcabene tablets administered orally once daily, for 12 weeks. |
| DRUG | Placebo | Placebo tablets administered orally once daily, for 12 weeks. |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-01-11
- Completion
- 2018-05-09
- First posted
- 2016-10-25
- Last updated
- 2020-06-25
- Results posted
- 2020-06-25
Locations
49 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02944383. Inclusion in this directory is not an endorsement.